KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $3.7 billion.

  • Regeneron Pharmaceuticals' Free Cash Flow rose 35.07% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 22.73%. This contributed to the annual value of $3.7 billion for FY2024, which is 5.44% down from last year.
  • Regeneron Pharmaceuticals' Free Cash Flow amounted to $3.7 billion in FY2024, which was down 5.44% from $3.9 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Free Cash Flow registered a high of $6.5 billion during FY2021, and its lowest value of $2.0 billion during FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Free Cash Flow value was $3.9 billion (recorded in 2023), while the average stood at $4.0 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 225.90% in 2021, then plummeted by 32.23% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Free Cash Flow (Yearly) stood at $2.0 billion in 2020, then soared by 225.90% to $6.5 billion in 2021, then crashed by 32.23% to $4.4 billion in 2022, then fell by 12.42% to $3.9 billion in 2023, then dropped by 5.44% to $3.7 billion in 2024.